The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 462.50
High: 462.50
Low: 462.50
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NHS Supply Chain listing

7 Nov 2008 07:00

RNS Number : 6707H
Tristel PLC
07 November 2008
 



 

TRISTEL plc

AIM: TSTL

High-level disinfection products for surfaces recommended by the NHS

Tristel Plc, a leading provider of infection control products into the NHS and private health sector, announces that the innovative product Fuse for Surfaces has been included in the NHS Supply Chain Catalogue and will be made available to all NHS organisations. This follows widespread adoption of Fuse for Surfaces during the course of the past 12 months by individual NHS hospitals sourcing the product directly from Tristel.

Tristel's chlorine dioxide solutions have been used in NHS endoscopy departments since the withdrawal of baldheads in the late 1990's. Chlorine dioxide (sometimes confused with chlorine but distinctly different), a well documented, highly effective, safe biocide is a powerful oxidising agent and is rapidly effective against all micro-organisms, including Clostridium difficile spores

Tristel has packaged its chlorine dioxide technology into a unique, easy to use 'burstable sachet'. Fuse for Surfaces delivers high-level disinfection of floors, walls and general hard surfaces in hospitals. No counting, weighing or calculations are needed to make up a working solution at the right concentration - and no waiting for chlorine tablets to dissolve. 

Paul Swinney, CEO of Tristel, said:

"Tristel offers a range of products, delivered in a variety of convenient formats that meet the individual decontamination needs that arise in endoscopy; ear, nose and throat; ultrasound; reproductive health and dentistry. Others tackle the challenges of disinfecting hospital and laboratory surfaces. We are especially pleased to have secured a place in the NHS Supply Chain Catalogue with our surfaces range of products".

Contacts:

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive

Daniel Stewart & Company Plc

Tel: 020 7776 6550

Graham Webster

Parkgreen Communications Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@parkgreenmedia.com

About Tristel

Tristel uses proprietary chlorine dioxide chemistry to create instrument and surface disinfectants. With its origins as a healthcare business specialising in infection control products, Tristel has recently extended its operations to include legionella control in water supplies and contamination control in the food and pharmaceutical industries. 

The company is creating applications for its chemistry that address the four routes of transmission of infection and contamination - surfaces, instruments, water and people.

Tristel plc has its headquarters in NewmarketUK and a network of distributors around the world. The company was admitted to trading on AIM on 1 June 2005. Its stock exchange symbol is TSTL.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDQLFBVFBEFBB
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.